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Abstract 
The m-TOR inhibitor sirolimus is an immunosuppressive drug used in kidney 
transplantation. m-TOR binds with Raptor and phosphorylates p70S6 kinase, a protein 
involved in numerous cell signalling pathways. We investigated the association of 
candidate polymorphisms in m-TOR, Raptor and p70S6K, sirolimus dose and exposure, 
and other time-independent as well as time-dependent covariates, with sirolimus-induced 
adverse events in kidney transplant recipients. This study included a first group of 113 
patients, switched from a calcineurin inhibitor to sirolimus and a validation group of 66 
patients from another clinical trial, with the same immunosuppressive regimen. The 
effects of gene polymorphisms and covariates on total cholesterol, low-density 
lipoprotein cholesterol, triglycerides, hemoglobin, cutaneous adverse events, oedemas 
and infections were studied using multilinear regression, or logistic regression imbedded 
in linear mixed-effect models. An m-TOR variant haplotype was significantly associated 
with a decrease in hemoglobin levels in the two populations of patients (discovery group: 
β=-0.82 g/dl, p=0.0076; validation group: β=-1.58 g/dl, p=0.0308). Increased sirolimus 
trough levels were significantly associated with increased total cholesterol levels 
(discovery group: β =0.02 g/l, p<0.0001, validation group: β =0.02 g/l, p=0.0002) and 
triglyceride levels (discovery group: β =0.02 g/l, p=0.0059, validation group: β =0.05 g/l, 
p=0.0370). Sirolimus trough levels were also associated with an increased risk for 
cutaneous adverse events (OR=1.97, 95%CI [1.32-1.94], p=0.0009) and oedemas 
(OR=1.16, 95%CI [1.03-1.30], p=0.01342) in the discovery group, but this was not 
confirmed in the validation group. These results provide evidence of an association 
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between an m-TOR haplotype and a decrease in hemoglobin in renal transplant 
recipients. 
 
Keywords: sirolimus, adverse event, mammalian target of rapamycin, p70S6 kinase, 
raptor, pharmacogenetics. 
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Introduction 
Sirolimus (SRL) is an immunosuppressive drug used in solid organ transplantation. Its 
use is restricted because of adverse effects [1], the most frequent of which are anemia, 
cutaneous lesions (cutaneous AEs), oedemas and dyslipemia [2-4]. Pneumonitis is very 
rare but could be fatal [5]. SRL binds to the FK506 binding protein (FKBP12) and this 
binary complex inhibits the mammalian target of Rapamycin (m-TOR), a protein kinase. 
The m-TOR protein is included in two complexes, m-TORC1 and m-TORC2, of which 
only the former is sensitive to SRL [6]. m-TORC1 contains 3 proteins: m-TOR, a G 
protein beta-subunit-like protein and the Regulatory Associated Protein of m-TOR 
(Raptor). Inhibition of m-TORC1 by SRL modulates cell growth and proliferation, as 
well as metabolic homeostasis [7] through the phosphorylation and inhibition of the 
eukaryotic initiation factor 4E binding protein (4E-BP1) and the phosphorylation and 
activation of the p70 ribosomal protein S6 kinase (p70S6K) [8, 9]. Given the major role 
of m-TORC1 in many different metabolic pathways, its inhibition might contribute to 
SRL AEs. In particular, lipid disorders might be directly linked to the m-TOR 
downstream signaling pathway, as it integrates inputs from multiple origins including 
nutrients, energy and insulin [10]. Sirolimus induced lymphoedemas seem to be linked to 
the impairment of VEGF-A downstream signal through the inhibition of the 
mTOR/p70S6K pathway by sirolimus [11]. Most of these adverse effects develop with 
time during maintenance treatment with SRL. Consequently, the study of such effects 
requires investigating the combined effects of the drug exposure level, duration and dose. 
To our knowledge, no study has investigated the association of genetic polymorphisms in 
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proteins of the mTOR pathway and SRL effects in transplant patients with a longitudinal 
follow-up. 
The gene encoding m-TOR (MTOR) is located on chromosome 1p36 and contains 58 
exons. Thirty five single nucleotide polymorphisms (SNPs) have been described in this 
gene (data from the Hapmap project, www.hapmap.org, version 3, release 27, panel 
CEU), with strong linkage disequilibrium. Five of these SNPs (Tag SNPs) give rise to six 
MTOR haplotypes. The gene encoding p70S6K (RPB6KB1) is located on chromosome 
17q23.1 and is made up of 15 exons. Seventeen SNPs have been described for this gene, 
with 5 tag SNPs able to discriminate 5 different alleles. The gene encoding Raptor 
(RPTOR) is located on chromosome 17q25 and has a more complex structure, with 25 
blocks containing 237 SNPs. A Raptor SNP affecting signal transduction has recently 
been described [12] and 3 SNPs have been associated with the risk of bladder cancer 
[13].  
The objective of this work was to study in kidney transplant recipients with a longitudinal 
follow-up the association of m-TOR, Raptor and p70S6K polymorphisms, sirolimus dose 
and exposure, demographics, laboratory tests and other treatment covariates on the one 
hand, with lipid plasma levels, hemoglobin (Hb), cutaneous AEs, oedemas and infections 
on the other.  
 
Methods 
Data were collected from patients who participated in two trials. Both studies complied 
with the declaration of Helsinki and were approved by ethics committees. A written 
informed consent was obtained from each patient enrolled. The influence of MTOR, 
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RPS6KB1 and RPTOR polymorphisms, individual laboratory test results and SRL 
exposure and dose was first investigated in patients included in the “discovery study”. 
The “validation study” intended to test the replication of the first study findings in a 
different population of patients. 
Discovery study: patients and data 
Between October 2000 and December 2008, 180 kidney-transplant patients were 
switched from a calcineurin inhibitor to sirolimus at least 3 months after transplantation. 
Among these patients, all those who later attended our outpatient clinic and who gave 
their informed consent were included in the study, whether they were still receiving SRL 
or not (n=113). A blood sample was drawn from each patient for genetic analyses. All 
patients included in the study were aged > 18 years, had a functioning graft, and had 
received sirolimus for at least 3 months. None of the patients had sirolimus stopped 
within the first 6 months post-conversion for uncontrolled adverse events. For each 
patient, the following clinical data were recorded: date of graft and date of SRL 
introduction, age, gender, initial nephropathy, time on dialysis before transplantation, 
number of kidney transplantation procedures, presence and date of occurrence of 
cutaneous AEs, lymphoedemas, and infections. Infections were defined as severe 
infections, respiratory or not, requiring hospitalization. Cutaneous AEs were defined as 
cutaneous lesions, folliculites, aphthous stomatitis, macula-papular and squamous lesions, 
and acne. Oedemas were also collected from the clinical files. Additionally the doses of 
all immunosuppressants including steroids (if any), serum creatinine level, leukocyte 
count, Hb, mean corpuscular volume (MCV), total cholesterol (tCHL), low-density –
lipoprotein cholesterol (LDL-C), triglyceride (TRG) plasma levels and the dose and type 
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of statins were retrospectively collected from patient charts at several periods: three 
months before the switch, on SRL introduction, and then 1, 3 and 6 months after the 
switch to sirolimus. Dyslipemia and anemia were studied as continuous variables, using 
the tCHL, TRG, LDL-C plasma levels and Hb blood level. Statins administration was 
categorized in 4 strata: no statin (statins=0), low dose of statins (statins=1; 10 mg/day of 
pravastatin, simvastatin or atorvastatin), middle dose of statins (statins=2; 20 or 30 
mg/day of pravastatin and 20 to 40 mg/day of simvastatin or atorvastatin) and high dose 
(statins=3; 40 mg/day of pravastatin and 50 to 80 mg/day of simvastatin or atorvastatin). 
Pneumonitis was not studied because only 4 cases were reported in this study. 
 
Validation study: patients and data  
The second group consisted of 66 patients treated by SRL and MMF and included in 
CONCEPT, an open-label, randomized, multicenter trial conducted in 16 French centres 
between November 2004 and October 2006 (Eudract-N° 2004-002987-62). Inclusion 
criteria, basal immunosuppressant therapy and the results of the main study were 
described elsewhere [14]. 
Patients were treated with MMF and cyclosporine A (CsA) from day 0 to week 12 and 
then randomized at week 12 between: continuation on CsA (patient group not studied in 
this work); or switch to SRL, with a loading dose of 10 mg/day for 2 consecutive days 
followed by 6 mg daily, adjusted to maintain C0 blood levels between 8 ng/mL and 15 
ng/mL from week 12 to week 39, then between 5 ng/mL and 10 ng/mL after week 39. 
Oral steroids were planned to be discontinued 8 months post-transplantation. All patients 
had SRL C0 measurements made at weeks 13, 14, 16, 26, 39 and 52. LDL and HDL 
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cholesterol, TRG and hemoglobin levels and body weight were noted at each visit, before 
(day 0 and weeks 4, 8 and 12 post-transplantation) and after SRL introduction (weeks 13, 
14, 16 to 26, 39 and 52). Cutaneous AEs (including aphthous stomatitis, folliculitis and 
acne), oedema and infections were collected from patients‟ clinical research files.  
 
SNP selection and identification of genotypes 
Genomic DNA was extracted from EDTA-treated blood using the QIAamp DNA Blood 
Mini kit (QIAGEN S.A., Courtaboeuf, France). Tagging SNPs were selected using the 
Haploview tagger algorithm [15], (version 2, release 24, panel CEU), with a cut-off of 
0.80 for r² and a minimum minor allele frequency more than 0.01, based on data from 
samples genotyped by the Hapmap project (www.hapmap.org) [16]. A total of 5 SNPs in 
MTOR (rs1770345, rs2300095, rs2076655, rs1883965 and rs12732063), 5 SNPs in 
RPS6KB1 (rs8071475, rs2526354, rs1292034, rs180535, rs8067568) were selected to 
represent the genetic variations of MTOR (35 tagged SNPs) and RPS6KB1 (17 tagged 
SNPs). Four RPTOR SNPs (rs2289759, rs7212142, rs7211818, rs11653499) were 
selected based on the literature [12, 13]. Genotypes were characterized using TaqMan 
Real-Time Polymerase Chain Reaction discrimination assay (ABI PRISM 7000 Sequence 
Detection System; Applied Biosystems, Courtaboeuf, France) following the 
manufacturer‟s protocol. Assays were ordered from Applied-Biosystems as functionally 
tested assays (references C__15753976_10, C__15866804_10, C__2562807_10, 
C__26761742_10, C___347870_10, C__2562791_10, C__43730643_10, 
C__15882533_10, C_11647372, C__441451_20, C__1971406_10, C___1971465_10, 
C__29221695_10, C__135233_10). 
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Statistical analysis  
The statistical analyses were performed using R software version 2.10.1 (R foundation 
for statistical computing, http://www.r-project.org). Deviations from the Hardy-Weinberg 
equilibrium were assessed using the Hardy-Weinberg exact test with the package 
“SNPassoc”. Linear mixed effect models were fitted using the “lme4” package.  Four 
continuous phenotypes (tCHL, TRG, LDL-C and Hb levels) and 3 binary phenotypes 
(infection, oedema, cutaneous adverse events) were studied using data collected before 
SRL introduction, at the time of SRL introduction and at different time-points post-
introduction, as described above. Random effects were included on both the baseline 
value (before SRL introduction; intercept) and the different following visits (slope). Time 
independent covariates (age at the inclusion, gender, time post grafting and m-TOR, 
p70S6K and Raptor SNPs or haplotypes), as well as covariates measured over time 
(steroid administration (yes/no), steroid dose, SRL dose, SRL trough concentration, and 
statins (in model including dyslipemia) or EPO prescription/blood transfusion (in model 
including Hb)) were studied as follows. In a first step, each covariate was tested as a 
fixed effect in univariate analysis. In the second step, all the significant covariates with 
p<0.2 in the univariate analysis were included simultaneously in an intermediate 
multivariate model, and then each covariate was removed from the intermediate model to 
confirm its relevance using the likelihood ratio test (backward deletion strategy).  
For association analyses of SNPs and haplotypes, the most frequent allele was considered 
as the reference. A dominant genetic model was chosen when the frequency of 
homozygotes for the ancestral allele (as reported in the NCBI database) was less than 5% 
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and a recessive genetic model when the frequency of homozygotes for the variant allele 
was less than 5%. In the other situations, an additive model of inheritance was chosen. 
After SNP association analysis, the p70S6K, Raptor and m-TOR haplotypes were 
investigated using the “haplo.stat” package and the haplotype frequencies in our 
population were compared to the Hapmap frequencies using the Chi-square test.  
Haplotype analysis was performed using linear regression and a log-additive genetic 
model for each of the visits studied in the discovery population (3 months before, on SRL 
introduction, and then 1, 3 and 6 months after). A haplotype significantly associated with 
a given AE at more than 2 visits was considered to be potentially at risk and was included 
in the multivariate analysis as a three categorical dummy variable (i.e. homozygous 
carriers, heterozygous carriers or non-carriers). The normality of continuous phenotype 
distribution (tCHL, LDL-C, TRG and Hb) was assessed by both visual examination of the 
probability density function and by the Shapiro-Wilk test. Classically, the linearity of 
continuous parameters was studied by comparing a nested quadratic model (a+ β1x1+ 
β2x1
2
) and a linear model (a+ β1x1) by likelihood ratio tests. All statistical analyses were 
two-sided, and p<0.05 was considered statistically significant. 
 
Results 
Clinical data 
Patient characteristics at the time of the switch from a calcineurin inhibitor to sirolimus 
are described in Table 1 (time-independent covariates), Table 2 and in supplemental 
digital content (Table S1) (time-related covariates). For some patients, covariate values 
were missing completely at random. A high rate of missing LDL-C levels was observed 
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in the discovery group, which is presumably because this analysis is less routinely 
performed as compared to total CHL or TRG. No significant deviation from normality 
was found for tCHL TRG, LDL-C or Hb level distributions. Significant deviation from 
linearity was observed for: the time post-SRL introduction in the models investigating 
cutaneous AEs, oedemas, Hb and TRG levels; and for SRL trough levels in the model 
investigating the cutaneous AEs. Consequently, a quadratic model was used for these 
analyses.  
Genotype/haplotype distribution 
Genotyping results were in the Hardy-Weinberg equilibrium and similar to those reported 
in Hapmap. 
The p70S6K rs2526354, rs180535, rs8067568 and m-TOR rs12732063 SNPs were 
studied using a dominant genetic model. Raptor rs2289759 and rs7211818 were studied 
using a recessive genetic model. All other SNPs were studied using an additive model. 
The m-TOR, Raptor and p70S6K haplotype frequencies found in our population were 
similar to those reported in Hapmap (See supplemental digital content: Table S2).  
 
Multivariate association analysis of pharmacogenetics and clinical covariates with 
SRL AEs (Table 3) 
 
Pharmacogenetics 
In the final multivariate model obtained in the discovery group adjusted on time post-
SRL introduction and EPO prescription, the following factors were significantly 
associated with a decrease of Hb level: (i) SRL trough levels (p=0.0203); (ii) the time 
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between transplantation and SRL introduction (p=0.0188); and (iii) m-TOR AGAAA 
haplotype (rs1770345/rs2300095/rs2076655/rs1883965/rs12732063) (p=0.0076) 
occurring at a frequency of 0.055. Moreover, the decrease of Hb level was associated 
with a decrease of the MCV, characterizing a microcytosis (Table 2). Figure 1 shows the 
difference in Hb levels between the two haplotype groups over the follow-up period. No 
association was found between Hb levels and m-TOR, p70S6K or Raptor polymorphisms 
studied as SNPs. In the validation study, the m-TOR AGAAA haplotype (p=0.0308) and 
the time post-SRL introduction (p=0.0270) were also significantly associated with a 
decrease in Hb levels (Figure 1). Contrary to what was observed in the discovery study, 
SRL trough levels were associated with increased Hb levels. 
No association was found between tCHL, TRG, LDL, infection, cutaneous AEs and 
oedema and m-TOR, p70S6K or Raptor polymorphisms, whether studied as SNPs or 
haplotypes. 
  
Non genetic factor and AEs 
In the discovery population, multivariate linear regression adjusted on the time post-SRL 
introduction, statin dose strata and steroid administration, showed that SRL trough levels 
were significantly and positively associated with tCHL (p<0.0001), TRG (p=0.006) and 
LDL (p=0.006) levels. This effect of increased tCHL (p<0.0001) and TRG (p=0.0370) 
levels with increased SRL trough levels was confirmed in the validation population.  
Logistic regression adjusted on the time post-SRL introduction in the discovery 
population showed that SRL trough levels were associated with oedemas (p=0.0134) in 
addition of patient age at the time of SRL introduction (p=0.0022), as well as with 
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cutaneous AEs (p=0.0009).  However, such associations were not found in the validation 
population. 
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Discussion 
We found a significant association between an m-TOR variant haplotype and decreased 
Hb levels in renal transplant patients on sirolimus and confirmed the previously published 
relationships between SRL trough levels and dyslipemia [17], cutaneous AEs [3], 
oedemas [11] and decreased Hb levels [2].  
We used a longitudinal design and mixed effect modeling, particularly appropriate to 
model the impact of time-dependent drug exposure, together with demographic, clinical, 
biological and genetic covariates on the occurrence of adverse effects.  
To the best of our knowledge, this is the first association study between m-TOR, p70S6K 
and Raptor gene polymorphisms, sirolimus administration and sirolimus adverse events 
in kidney transplant patients with a longitudinal follow-up. The polymorphisms and 
haplotypes studied, based on those reported during the Hapmap project, were 
representative of the whole m-TOR and p70S6K genes, and those chosen for Raptor had 
previously been associated with bladder cancer or with changes in Raptor activity in vitro 
[12, 13]. 
We found that the AGAAA (rs1770345/rs2300095/rs2076655/rs1883965/rs12732063) 
m-TOR haplotype (frequency=0.055), in addition to SRL trough levels, was strongly 
associated with decreased Hb levels. The effect of this haplotype was confirmed in an 
independent group of patients, contrary to that of SRL through levels, which were 
inversely associated with Hb levels in the validation group. We have no explanation for 
this discrepancy. It is noteworthy that the effect of the haplotype was statistically 
independent of EPO prescription/blood transfusion because no effect of this factor or 
interaction with the haplotype effect was found. It has been shown that the inhibition of 
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m-TOR by SRL leads to a diminution of erythroïd cell lines proliferation in vitro [18]. A 
hypothesis proposed by Fishbane is that SRL could result in early differentiation of 
erythroid precursors and diminished globin synthesis, leading to microcytic anemia [19]. 
Consistent with this hypothesis, we observed that patients treated by SRL experienced a 
concentration-dependent microcytosis. A possible mechanism could be that carriers of the 
AGAAA m-TOR haplotype have a basal decrease in m-TOR activity and/or level, 
associated with an early differentiation of erythroid precursors and that the introduction 
of sirolimus leads to a higher decrease of Hb in the AGAAA group compared to the other 
groups. In this case, this haplotype could also possibly be associated with an increased 
SRL treatment efficacy through decreased mTOR activity, but we have no data yet to 
support this hypothesis.  
We found no association between m-TOR, p70S6K or Raptor genetic polymorphisms and 
lipid levels but we confirmed the previously reported [17, 20] proportionality between 
sirolimus trough levels and tCHL, LDL-C and TRG plasma levels. Only one study had 
previously quantified this relationship using a longitudinal follow-up in 280 renal 
transplants treated de novo by SRL, CsA and prednisolone [20]. The authors concluded 
that dyslipemia (hypercholesterolemia or hypertriglyceridemia) was associated with SRL 
through levels, but not dose [20], a finding we confirmed here in two independent groups 
of patients.  In the discovery population, the patients with the highest levels of tCHL or 
LDL-C received the highest statin doses, the latter being probably a consequence of the 
former. We also found the well-known increase in tCHL cholesterol associated with 
corticosteroids in the discovery and in the validation groups, and the previously reported 
difference in LDL-C level between men and women [21] in the discovery group only. 
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Other associations with SRL AEs were also found only in the discovery group but again, 
m-TOR, p70S6K or Raptor genetic polymorphisms were not contributory. (i) The time 
post-SRL introduction was the only factor associated with infections. The occurrence of 
infections is indeed more likely to be influenced by a combination of the overall 
immunosuppressive effect (rather than specifically that of SRL) and of the probably of 
encountering infectious microorganisms (hence time). (ii) Cutaneous adverse events were 
strongly associated with SRL trough levels. This association is well known in clinical 
practice. (iii) SRL trough levels, age and time post-SRL introduction were significantly 
associated with oedema. It was previously hypothesized that SRL may lead to a reduction 
of VEGF production and/or to the inhibition of the growth of vascular smooth-muscle 
cells, which would secondarily trigger oedemas [3]. We could confirm here the 
concentration-related nature of this AE, consistent with the usual SRL dose decrement in 
the case of oedemas. 
There were thus a number of differences between the results of the discovery and the 
validation studies regarding cutaneous AEs and oedemas. There are several possible 
explanations for these differences. First, the design of the discovery study was 
specifically focused on SRL AEs which led to an exhaustive screening of patient files. In 
contrast, the patients of the validation group had been enrolled in a randomized clinical 
trial with a different principal objective (study of renal function), which presumably 
resulted in a difference in AEs reporting and with close therapeutic drug monitoring of 
SRL. Secondly, there were twice as many patients in the discovery than in the validation 
study.  
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Our hypothesis was that individual or combinations of polymorphisms in the major genes 
of SRL pharmacodynamic pathway could influence patients‟ sensitivity to SRL and thus 
their likelihood to experience adverse events, independently of SRL levels, treatment 
duration and other confounding factors (e.g. steroids, statins or EPO administration…). 
We thus performed a stepwise multivariate procedure which allowed us to investigate the 
additional value of a given gene polymorphism by adjusting the model on other 
polymorphisms or non-genetic factors. Although a stepwise procedure decreases the 
number of tests performed as compared to univariate testing of each variable on each 
phenotype, it still leads to multiple testing. Consequently, we cannot formally exclude 
that false positive findings occurred here. However, the main results were confirmed in 
an independent dataset of patients, which is a strong argument against chance findings. In 
either group of patients, m-TOR, p70S6K or Raptor genetic polymorphisms had no effect 
on SRL AEs, except for the abovementioned m-TOR variant haplotype on Hb levels. The 
present study has certain limitations. Although two independent groups of patients were 
considered, both have a relatively small sample size. This is primarily due to the 
restricted use of the drug because of adverse events. Another limitation is the 
retrospective nature of the discovery study, with data collection from patient files. In 
contrast, for the confirmation study, clinical data were reported in a CRF and gathered in 
a prospectively built electronic database.  
We have also to acknowledge that not all the precursors and effectors in the m-TOR 
signaling pathway were studied. However, we focused on proteins which interact directly 
with sirolimus: m-TOR is the principal target of SRL, Raptor is the regulatory protein 
associated to m-TOR in the m-TORC1 complex and p70S6K was previously chosen as a 
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biomarker of SRL m-TOR inhibitory effect [22]. On the other hand, the 4EBP1 effectors 
inhibited by the phosphorylation of m-TOR have never been investigated. The study of 
other precursors or effectors might be less specific as they are only indirectly related to 
SRL activity.  
In conclusion, our study provides evidence in favor of an association between the 
reduction of Hb and an m-TOR haplotype, in addition to SRL exposure. Prospective 
studies have to be performed in order to evaluate the effect of this haplotype on SRL 
efficacy, or rather benefit/risk ratio. We also confirmed the SRL concentration-related 
nature of dyslipemia, but identified no polymorphisms in m-TOR, p70S6K and Raptor 
which would result in an individual susceptibility to such AEs.  
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Table 1- Characteristics of the kidney transplant patients enrolled in the studies at the 
time of switch to sirolimus  
Covariates Discovery study Validation study 
Age 
mean±sd 
n 
 
52±14 years 
113 
 
47±12 years 
66 
Time between 
transplantation and 
conversion to sirolimus 
 
mean±sd 
min-max 
n 
 
 
 
 
5.9±5.9 years 
0.3-25.9 
113 
 
 
 
 
90.8±8 days 
77-116 
66 
Sex ratio 
Male/Female 
 
80/33 
 
46/20 
Rank of kidney 
transplantation 
-1: n (%) 
-2: n (%) 
-3: n (%)  
 
 
102 (90%) 
10 (9%) 
1 (1%) 
 
 
66 (100%) 
Calcineurin inhibitor (CNI) 
given before SRL  
Cyclosporine A 
n (%) 
daily dose (mean ±sd) 
Tacrolimus 
n (%) 
daily dose (mean ±sd) 
 
 
 
 
73 (65%) 
178±58 mg 
 
40 (35%) 
3.8±2.0 mg 
 
 
 
66 (100%) 
Variables normally distributed are expressed as mean±sd and those not normally 
distributed as median (range).
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Table 2- Characteristics of the discovery population for time-related data, 3 months before (M-3), 
at the time of sirolimus (SRL) introduction (M0), and 1, 3 and 6 months (M1, M3, M6)* after. 
 M-3 M0 M1 M3 M6 
tCHL (g/L) 
n (available) 
mean±sd  
min-max 
 
94 
1.87±0.40 
0.80-3.52 
 
101 
1.81±0.40 
0.86-2.75 
 
99 
2.05±0.43 
1.10-3.49 
 
93 
2.15±0.48 
0.98-3.57 
 
90 
2.07±0.41 
1.03-2.83 
LDL-C (g/L) 
n (available) 
mean±sd  
min-max 
 
68 
0.99±0.31 
0.34-1.72 
 
59 
0.88±0.36 
0.18-1.94 
 
61 
1.06±0.40 
0.25-2.03 
 
69 
1.19±0.44 
0.22-2.17 
 
73 
1.15±0.40 
0.15-2.00 
TRG (g/L) 
n (available) 
mean±sd  
min-max 
 
93 
1.45±0.77 
0.50-4.91 
 
101 
1.58±0.96 
0.41-6.38 
 
100 
1.87±0.921.05 
0.46-4.53 
 
94 
1.98±0.88 
0.53-4.79 
 
89 
1.93±1.07 
0.41-7.46 
Statins dose group 
0 n (%) 
1 n (%) 
2 n (%) 
3 n (%) 
 
50 (44.2) 
31 (27.4) 
23 (20.3) 
9 (8.0) 
 
47 (41.6) 
27 (23.9) 
27 (23.9) 
12 (10.6) 
 
42 (37.2) 
30 (26.6) 
25 (22.1) 
16 (14.1) 
 
41 (36.3) 
32 (28.3) 
23 (20.3) 
17 (15.1) 
 
37 (32.7) 
34 (30.1) 
23 (20.3) 
19 (16.8) 
SRL trough level 
(ng/mL) 
n (available) 
mean±sd 
 
 
NA 
 
 
NA 
 
 
106 
10.5±3.9 
 
 
97 
9.8±4.3 
 
 
98 
9.8±3.7 
SRL dose (mg) 
n (available) 
mean±sd 
 
NA 
 
NA 
 
110 
3.0±1.2 
 
101 
3.0±1.2 
 
96 
3.0±1.3 
Steroids  
yes/no 
mean dose±sd (mg) 
min-max 
 
 90/19 
7.9±4.4 
1-20 
 
94/19 
7.9±5.1 
1.25-30 
 
97/16 
7.5±4.2 
1-30 
 
86/14 
7.5±5.3 
2-40 
 
87/10 
6.2±3.0 
2-20 
Mycophenolic acid 
yes/no 
mean dose±sd (mg) 
min-max 
 
83/26 
1524±539 
500-3000 
 
83/30 
1454±464 
500-2000 
 
84/29 
1394±477 
500-3000 
 
74/27 
1266±435 
500-2000 
 
72/25 
1221±391 
500-2000 
Serum creatinine 
(µmol/L) 
n (available) 
mean±sd 
 
 
106 
156±100 
 
 
112 
161±97 
 
 
110 
136±38 
 
 
97 
141±42 
 
 
97 
139±42 
Leukocyte (G/L) 
n (available) 
mean ±sd 
 
103 
7.1±2.4 
 
106 
7.1±2.8 
 
107 
5.6±2.2 
 
77 
6.0±2.2 
 
74 
6.2±2.3 
Hemoglobin (g/dL)  
n (available) 
mean±sd 
 
105 
12.9±1.7 
 
106 
12.9±1.5 
 
108 
12.4±1.3 
 
78 
12.3±1.3 
 
76 
12.8±1.3 
Mean Corpuscular 
volume (fl) 
n (available) 
mean±sd  
 
 
96 
90.7±5.6 
 
 
102 
90.7±4.5 
 
 
103 
88.4±4.8 
 
 
76 
85.7±5.1 
 
 
72 
82.4±4.4 
Infection 0 (0%) 0 (0%)  4 (3%) 3 (3%) 25 (22%) 
Cutaneous AEs 0 (0%) 2 (2%) 26 (23%) 7 (6%) 8 (7%) 
Oedema 0 (0%) 0 (0%) 2 (2%) 7 (6%) 11 (10%) 
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*the number of patients was different between visits due to missing values totally at random. tCHL is total 
cholesterol, LDL-C is low density lipoprotein cholesterol, TRG is triglycerides. Statins dose group: „0‟: no 
statins, „1‟ low dose of statins (10 mg of pravastatin, simvastatin or atorvastatin), „2‟: middle dose of statins 
(20 or 30 mg of pravastatin and 20 to 40 mg of simvastatin or atorvastatin) and „3‟: high dose (40 mg of 
pravastatin and 50 to 80 mg of simvastatin or atorvastatin).  
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Table 3- Multivariate Linear Mixed Effects Regression analyses  for total cholesterol (tCHL), triglyceride(TRG) low-density-
lipoprotein plasma-cholesterol (LDL-C), hemoglobin, infections, cutaneous adverse events and oedemea in the discovery study and in 
the validation study,  using final discovery study models.  
 
   Discovery study Validation study 
Covariates Category 
Adjusted β 
coefficient 
Adjusted s.e. Adjusted p 
Adjusted β 
coefficient 
Adjusted s.e. Adjusted p 
Multivariate analysis tCHL 
Intercept  1.710 0.071 <0.0001 1.441 0.215 <0.0001 
Time post-SRL 
introduction 
Per inter-visit delay 0.011 0.007 0.5768 0.007 0.004 0.0791 
Statin group 
1 vs 0 
2 vs 0 
3 vs 0 
0.030 
0.040 
0.154 
0.057 
0.062 
0.075 
0.5124 
0.3156 
0.0358 
Non available Non available Non available 
SRL trough level Per 1 ng/ml increase 0.017 0.003 <0.0001 0.021 0.006 <0.0001 
Steroids Yes vs No 0.152 0.068 0.0249 0.547 0.126 <0.0001 
Multivariate analysis TRG 
Intercept  1.599 0.080 <0.0001 0.630 1.055 0.5510 
Time post-SRL 
introduction 
 0.050 0.019 0.0111 0.083 0.061 0.1650 
Î(Time post-SRL 
introduction ²) 
 -0.005 0.003 0.1399 -0.001 0.0008 0.1250 
SRL trough level Per 1 ng/ml increase 0.020 0.007 0.0059 0.047 0.023 0.0370 
Multivariate analysis LDL-C 
Intercept  0.847 0.066 <0.0001 1.372 0.115 <0.0001 
Time post-SRL 
introduction  
Per inter-visit delay 0.010 0.007 0.6003 -0.007 0.002 <0.0001 
Gender M vs F 0.136 0.065 0.0388 0.107 0.088 0.2259 
SRL trough level Per 1 ng/ml increase 0.011 0.004 0.0058 0.007 0.005 0.2236 
Statin group 
1 vs 0 
2 vs 0 
3 vs 0 
-0.012 
0.041 
0.146 
0.058 
0.067 
0.074 
0.9999 
0.5183 
0.0455 
Non available Non available Non available 
Multivariate analysis hemoglobin 
Intercept  12.88 0.129 <0.0001 13.10 0.488 <0.0001 
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Time post-SRL 
introduction  
Per inter-visit delay -0.032 0.033 0.3371 -0.056 0.029 0.0270 
Î(Time post-SRL 
introduction ²) 
Per inter-visit delay 0.012 0.006 0.0358 0.001 0.0005 0.0281 
Haplotype 
rs1770345 A/ 
rs2300095 G/ 
rs2076655 A/ 
rs1883965 A/ 
rs12732063 A vs 
other 
-0.819 0.306 0.0076 -1.557 0.732 0.0308 
SRL trough level Per 1 ng/ml increase -0.032 0.014 0.0203 0.022 0.010 0.0010 
Delay transplantation/ 
SRL introduction 
Per year increase 0.035 0.015 0.0188 Non available Non available Non available 
EPO or blood 
transfusion 
Yes vs No 0.172 0.283 0.5420 -0.060 0.691 0.9500 
Covariates Category Adjusted OR Adjusted 95CI Adjusted p Adjusted OR Adjusted 95CI Adjusted p 
Multivariate analysis Infection 
Time post-SRL 
introduction  
Per inter-visit delay 1.82 1.48-2.23 <0.0001 1.00 1.00-1.00 0.4960 
Multivariate analysis Cutaneous adverse event 
Time post-SRL 
introduction  
Per inter-visit delay 0.79 0.48-1.29 0.3491 1.01 1.00-1.03 0.2750 
Î(Time post-SRL 
introduction ²) 
Per inter-visit delay 0.99 0.92-1.07 0.8832 1.00 0.99-1.01 0.8190 
SRL trough level Per 1 ng/ml increase 1.97 1.32-2.94 0.0009 1.00 0.99-1.01 0.2680 
I(SRL trough level²) Per 1 ng/ml increase 0.98 0.96-0.99 0.0007 1.00 0.99-1.01 0.2020 
Multivariate analysis oedema 
Time post-SRL 
introduction  
Per inter-visit delay 4.73 1.02-21.90 0.0466 1.01 1.00-1.02 0.0859 
Î(Time post-SRL 
introduction ²) 
Per inter-visit delay 0.85 0.70-1.03 0.0913 0.99 0.99-1.00 0.0605 
Age Per year increase 1.08 1.03-1.13 0.0022 1.00 0.99-1.01 0.3680 
SRL trough level Per 1 ng/ml increase 1.16 1.03-1.30 0.0134 1.00 0.99-1.01 0.8584 
There was no statistical interaction between covariates; SRL is sirolimus; β is the estimate of the regression coefficient and s.e. its standard error, OR is the Odd Ratio and 95CI the 95% confidence 
interval of the OR. Statins dose group: 0 no statins, „1‟: low dose of statins (10 mg of pravastatin, simvastatin or atorvastatin), „2‟: middle dose of statins (20 or 30 mg of pravastatin and 20 to 40 mg of 
simvastatin or atorvastatin) and „3‟: high dose of statins (40 mg of pravastatin and 50 to 80 mg of simvastatin or atorvastatin). CHL, TRG and LDL-C are in g/L, Hb is in g/dL. 
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Figure Legends 
Figure 1- Evolution of the hemoglobin level according to m-TOR haplotype AGAAA 
(rs1770345/rs2300095/rs2076655/rs1883965/rs12732063) vs others over the 
follow-up periods in the discovery and in the validation groups. 
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